Navigating the New Psoriasis Guidelines: Implications for Clinical PracticePremiere Date: Thursday, March 26, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- ABP (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, March 26, 2021
|Joel M. Gelfand, MD, MSCE (Moderator)
Professor of Dermatology and Epidemiology
Vice Chair of Clinical Research
Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
|Analisa Vincent Halpern, MD
Associate Professor of Medicine
Director, Dermatology Residency Program
Division of Dermatology
Cooper Medical School of Rowan University
|Lara Wine Lee, MD, PhD
Assistant Professor of Dermatology and Pediatrics
Medical University of South Carolina
The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) have recently released new joint guidelines that outline best practices for the management of psoriasis (PsO) with biologics, the need for awareness and attention to comorbidities, and guidelines for pediatric PsO treatment. Clinicians must ensure that they are aware of these guidelines and of strategies to incorporate them into clinical practice, including the integration of biologic therapy into treatment plans, the implementation of strategies to manage comorbidities, and the management of pediatric patients with PsO, in alignment with guideline recommendations.
In this interactive CMEO Live and On Demand webcast, leading experts in PsO will utilize clinical cases to illustrate real-life approaches that learners can apply in order to optimize incorporation of these latest recommendations into clinical practice.
At the end of this CE activity, participants should be able to:
- Integrate biologic therapy into treatment plans for appropriate patients with moderate-to-severe PsO, in accordance with the joint AAD-NPF guidelines.
- Implement strategies to manage comorbidities in patients with PsO as recommended by the joint AAD-NPF guidelines.
- Apply the joint AAD-NPF guidelines when managing pediatric patients with PsO.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe treatment plans for appropriate patients with moderate-to-severe PsO in accordance with the joint AAD-NPF guidelines.
- Explain strategies to manage comorbidities in patients with PsO, as recommended by the joint AAD-NPF guidelines.
- Identify the joint AAD-NPF guidelines when managing pediatric patients with PsO.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Dermatologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABP MOC Credit:
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gelfand reports that he receives grants from AbbVie Inc.; Boehringer Ingelheim; Celgene Corporation; Janssen Biologics, Inc.; Novartis Corporation; Ortho Dermatologics; and Pfizer Inc. He is a consultant for Boehringer Ingelheim; Bristol-Myers Squibb Company; Janssen Biologics, Inc.; NeuroDerm Data and Safety Monitoring Board (DSMB); Novartis Corporation; Pfizer Inc.; Sun Pharmaceutical Industries; and UCB Data and Safety Monitoring Board (DSMB). He receives other financial or material support as a Co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology.
Dr. Halpern has no disclosures to report.
Dr. Lee reports she receives research support from AbbVie Inc.; Amryt Pharma; Castle Creek Pharma; Eli Lilly and Company; Incyte; Mayne Pharma; Regeneron Pharmaceuticals, Inc.; Sanofi; and Trevi Therapeutics. She is a consultant for AbbVie Inc. and Pyramid Biosciences and on the advisory board for Eli Lilly and Company and Regeneron Pharmaceuticals, Inc.
Dr. Helfand (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).